MARKET

KZIA

KZIA

Kazia Therapeuti
NASDAQ
9.50
+0.23
+2.48%
Opening 14:40 10/05 EDT
OPEN
9.31
PREV CLOSE
9.27
HIGH
9.54
LOW
9.12
VOLUME
202.47K
TURNOVER
--
52 WEEK HIGH
17.40
52 WEEK LOW
4.860
MARKET CAP
144.83M
P/E (TTM)
-1.5659
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Kazia Therapeutics (KZIA) and FocalTherics (FOCL)
TipRanks · 4d ago
Weekly Report: what happened at KZIA last week (0921-0925)?
Weekly Report · 09/28 09:07
Analyst Reiterates Buy on Kazia Therapeutics, Maintaining $40 Price Target as Paxalisib Advances into Rare Epilepsy Trial
TipRanks · 09/23 09:55
Kazia Therapeutics Gains $2 Million Milestone as Sovargen Doses First Paxalisib Patient in Rare Epilepsy Trial
TipRanks · 09/22 12:27
Kazia Therapeutics licensee doses first patient in Phase 1b/2a paxalisib trial
TipRanks · 09/22 11:40
Kazia Therapeutics Announces Sovargen Doses First Participant In Phase 1b/2a Clinical Study Of Paxalisib To Treat Epilepsies
Benzinga · 09/22 11:33
Weekly Report: what happened at KZIA last week (0914-0918)?
Weekly Report · 09/21 09:07
Kazia Therapeutics Switches ADR Depositary to JPMorgan as ADSs Remain on Nasdaq
TipRanks · 09/18 20:44
More
About KZIA
Kazia Therapeutics Limited is an Australia-based pharmaceutical drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.

Webull offers Kazia Therapeutics Ltd (ADR) stock information, including NASDAQ: KZIA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KZIA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KZIA stock methods without spending real money on the virtual paper trading platform.